Genzyme Corporation is one of the world’s forerunner biotechnology companies which is devoted to developing the significant positive impact on the lives of the people having serious types of ailments. The company has been launched since 1981 and by now it is the known diversified enterprise having over 8,500 work force spread all over the globe.

Renvela is developed by the well known pharmaceutical player called Genzyme Corporation, as the next generation – advanced phosphate binder for substituting Renagel – Sevelamer Hydrochloride for controlling the serum phosphorus in the patients having chronic kidney ailments on dialysis. Sevelamer Carbonate is designated as Renvela for the United States markets replacing its ancestor Renagel – Sevelamer Hydrochloride. This is the non-calcium, non-metal, non-absorbed phosphate binder and is available in the strength of 800 mg in tablet form. 

Renagel is designed to control serum phosphorus in the patients with chronic kidney diseases - CKD on hemo-dialysis where the controlling of serum phosphorus in the hemo-dialysis is the most significant feature in the treatment of hemo-dialysis patients. Improved serum phosphorus levels are common in most of the dialysis patients and combined with the raised risk of cardiovascular deaths. This advance medication is posed to extend extra advantages of great importance like LDL cholesterol decrease by almost 32 percent.

Renagel possess the proven safety feature, it is not systemically absorbed and provides the phosphorus control without the concerns of calcium or metal accretion. This wonder drug is already being used by over 350,000 people in the different countries of the world. During the 52 week detailed study for this medication, the most common side effect that showed up include: vomiting, nausea, diarrhoea and dyspepsia.